CONCLUSION
IH are the most common benign vascular tumours. They are a cause of parental discomfort and anxiety and need to be carefully assessed from the treatment point of view. Most IH are uncomplicated and can be managed by active non-intervention alone. However, the recent encouraging reports of topical timolol in haemangiomas suggest that it can be advised even for uncomplicated localized lesions to accelerate the involution process. Systemic steroids have been considered the therapeutic mainstay for complicated haemangiomas for several decades. Recently, there have been several studies describing the efficacy and safety of propranolol in treating infantile haemangiomas. Though comparative studies between steroids and propranolol are few, a good therapeutic efficacy, even in the post-proliferation phase and a better side-effect profile has tilted the balance in favour of propranolol. Only future prospective trials involving a larger number of patients and a longer follow-up period will tell whether propranolol fulfils its therapeutic promise.
Q1. The maximum period of growth of infantile haemangiomas occurs at the following period:
First week after birth
Birth to 5 months
After 6 months
Birth to 1 year
Q2. PHACES syndrome is associated with facial segmental haemangioma and includes all except:
Posterior fossa abnormalities
Coarctation of the aorta
Sternal abnormalities
Oesophageal stenosis
Q3. The following infantile haemangiomas require treatment:
Ocular haemangiomas
Ulcerating haemangiomas
Nasal tip haemangiomas
All of the above
Q4. The first line of treatment of infantile haemangiomas is:
Systemic corticosteroids
Topical corticosteroids
Oral propranolol
Vincristine
Q5. Adverse effects of propranolol include all except:
Tachycardia
Hypoglycaemia
Bronchospasm
Hyperkalaemia
Answers online at www.jcasonline.com
CME QUESTIONS WITH ANSWERS  Click here for additional data file.